Published in Cancer Weekly, July 20th, 2004
TMD has been working along with the laboratory of Khandan Keyomarsi, studying cell cycle regulators in breast cancer. Work from this venture, which was published in the New England Journal of Medicine in November of 2002, highlighted the potential prognostic significance of cyclin E in patients with Stage I-III breast cancer.
In this latest collaboration, investigators at MDACC and TMD will be studying the relevance of cyclin E in predicting the outcome for patients undergoing liver surgery...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.